Yahoo Finanza Combination between Novozymes and Chr. Hansen approved by Novozymes’ shareholders
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART), IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH ACTION WOULD BE UNLAWFUL. |
MARCH 30, 2023
On December 12, 2022, Novozymes A/S ("Novozymes") and Chr. Hansen Holding A/S ("Chr. Hansen") announced that Novozymes and Chr. Hansen had entered into a merger agreement to combine by way of a statutory merger of the two companies (the "Combination"). Reference is made to Chr. Hansen's company announcement no. 13 of December 12, 2022.
Novozymes today announced that its Extraordinary Shareholders’ Meeting has approved the implementation of the Combination in accordance with the merger plan of December 12, 2022.
Chr. Hansen will hold an extraordinary general meeting later today at 5 pm (CEST) for the purpose of resolving on the implementation of the Combination. The outcome of Chr. Hansen’s extraordinary general meeting will be announced separately.
If the merger is approved by Chr. Hansen’s extraordinary general meeting, the completion of the Combination will remain subject to the satisfaction of a number of conditions, including certain regulatory approvals, and certain termination rights as further described in the exemption document published on March 8, 2023. The exemption document is available (with certain restriction) via the websites listed below.
For additional information on the proposed Combination, please visit www.power-with-biology.com or www.chr-hansen.com/en/investors/proposed-merger.
About Chr. Hansen
Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical, and agricultural industries. At Chr. Hansen, we are well positioned to drive positive change through microbial solutions. We have worked for over 145 years to enable sustainable agriculture, better food and healthier living for more people around the world. Our microbial and fermentation technology platforms, including our broad and relevant collection of around 40,000 microbial strains, have game-changing potential. Matching customer needs and global trends, we continue to unlock the power of good bacteria to respond to global challenges such as food waste, global health and the overuse of antibiotics and pesticides. As the world's most sustainable food ingredients company, we touch the lives of more than 1 billion people every day. Driven by our legacy of innovation and curiosity to pioneer science, our purpose – To grow a better world. Naturally. – is at the heart of everything we do.
About Novozymes
Novozymes is the world leader in biological solutions. Together with customers, partners, and the global community, we improve industrial performance while preserving the planet's resources and helping build better lives. As the world's largest provider of enzyme and microbial technologies, our bioinnovation enables higher agricultural yields, lowtemperature washing, energy-efficient production, renewable fuel, and many other benefits that we rely on today and in the future. We call it Rethink Tomorrow.
Please see attachment.
Contact information
Investor Relations
Anders Mohr Christensen
+45 2515 2364
dkamc@chr-hansen.com
Press Relations
Sanne Seyer-Hansen
+45 6038 6207
dksash@chr-hansen.com
Attachment
